Opthea Limited
NASDAQ: OPT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- Employees
- 33
- Headquarters
- South Yarra, Australia
- IPO year
- 2020
- Market cap
- $4.2B
- Website
- https://www.opthea.com
Loading OPT…
Loading profile data…Frequently asked questions about OPT
What does Opthea Limited (OPT) do?
Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D...
Where does OPT trade?
Opthea Limited (OPT) trades on the NASDAQ Global Select.
What sector is OPT in?
Opthea Limited (OPT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Opthea Limited?
Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir, is the chief executive officer of Opthea Limited (OPT).
Where is Opthea Limited headquartered?
Opthea Limited is headquartered in Australia.
Does OPT pay a dividend?
Opthea Limited (OPT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OPT go public?
Opthea Limited (OPT) completed its initial public offering in 2020.
Is OPT an ADR?
Yes — OPT is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Opthea Limited reporting and dividends follow the underlying issuer.